Article info
PDFClinical and epidemiological research
Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
- Professor E Keystone, Mount Sinai Hospital, 60 Murray Street, Room 2-006, Toronto, Ontario MST 3L9, Canada; edkeystone{at}mtsinai.on.ca
Citation
Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
Publication history
- Accepted November 23, 2008
- First published December 9, 2008.
Online issue publication
March 09, 2023
Article Versions
- Previous version (25 October 2017).
- Previous version (16 February 2018).
- You are viewing the most recent version of this article.
Web only appendices 68;6:789-796
Files in this Data Supplement:
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Keystone et al 2009 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.